Form 8-K - Current report:
SEC Accession No. 0001193125-21-106610
Filing Date
2021-04-06
Accepted
2021-04-05 18:45:02
Documents
14
Period of Report
2021-04-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d140370d8k.htm   iXBRL 8-K 24137
2 EX-99.1 d140370dex991.htm EX-99.1 41601
6 GRAPHIC g140370dsp1.jpg GRAPHIC 12776
  Complete submission text file 0001193125-21-106610.txt   219292

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20210405.xsd EX-101.SCH 3092
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20210405_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20210405_pre.xml EX-101.PRE 11422
7 EXTRACTED XBRL INSTANCE DOCUMENT d140370d8k_htm.xml XML 3365
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 21807312
SIC: 2836 Biological Products, (No Diagnostic Substances)